Technical Analysis for ALPMF - Astellas Pharma Inc

Grade Last Price % Change Price Change
grade A 17.41 0.00% 0.0000
ALPMF closed unchanged on Thursday, December 12, 2019, on 6 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
See historical ALPMF trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Bearish Engulfing Bearish 2.11%
Stochastic Sell Signal Bearish 2.11%
Slingshot Bullish Bullish Swing Setup 2.11%
Outside Day Range Expansion 2.11%
Older signals for ALPMF ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. It also provides Celecox, an anti-inflammatory agent; Lipitor, a treatment for hypercholesterolemia; Micardis/Micombi/Micamlo, a treatment for hypertension; Symbicort for the treatment for adult bronchial asthma and chronic obstructive pulmonary disease; Bonoteo for the treatment for osteoporosis; Suglat for the treatment of type 2 diabetes; and Repatha for the treatment of hypercholesterolemia. In addition, it offers Lexiscan, a pharmacologic stress agent; Tarceva, a treatment for non-small cell lung cancer; CRESEMBA, a azole antifungal; and Dificlir, a novel treatment for CDI. Additionally, it is developing enzalutamide, gilteritinib, enfortumab vedotin, zolbetuximab, roxadustat, and fezolinetant for oncology indications. The company has a collaboration with Actinium Pharmaceuticals, Inc. to apply Actinium warhead enabling technology platform for generating Actinium radio-conjugates with various Astellas targeting agents. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Chemistry RTT Diabetes Chemical Compounds Organic Compounds Prostate Cancer Hypertension Non Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Osteoporosis Benign Prostatic Hyperplasia Mitsubishi Ufj Financial Group Hypercholesterolemia Lactams Overactive Bladder Treatment Of Prostate Cancer Astellas Pharma Exports Pharmaceutical Products Hyperplasia Adult Bronchial Asthma Enzalutamide Tamsulosin Treatment For Hypertension Treatment For Non Small Cell Lung Cancer Treatment For Osteoporosis

Is ALPMF a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.76
52 Week Low 11.89
Average Volume 3,206
200-Day Moving Average 14.5779
50-Day Moving Average 15.0675
20-Day Moving Average 16.7095
10-Day Moving Average 16.9985
Average True Range 0.3049
ADX 19.27
+DI 48.7070
-DI 32.1770
Chandelier Exit (Long, 3 ATRs ) 16.5853
Chandelier Exit (Short, 3 ATRs ) 15.8147
Upper Bollinger Band 17.7328
Lower Bollinger Band 15.6862
Percent B (%b) 0.84
BandWidth 12.2481
MACD Line 0.6373
MACD Signal Line 0.6345
MACD Histogram 0.0028
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.4100
Resistance 3 (R3) 17.4100 17.4100 17.4100
Resistance 2 (R2) 17.4100 17.4100 17.4100 17.4100
Resistance 1 (R1) 17.4100 17.4100 17.4100 17.4100 17.4100
Pivot Point 17.4100 17.4100 17.4100 17.4100 17.4100
Support 1 (S1) 17.4100 17.4100 17.4100 17.4100 17.4100
Support 2 (S2) 17.4100 17.4100 17.4100 17.4100
Support 3 (S3) 17.4100 17.4100 17.4100
Support 4 (S4) 17.4100